Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$27,000.00

Evaluation of YKL-40 as a moderator variable between insomnia and the concentration of p-Tau217

FY 2024-25

Summary
YKL-40 is a molecule whose blood concentration varies according to the severity of inflammation. We will attempt to assess whether inflammation, measured by blood levels of YKL-40, moderates the association between insomnia and Alzheimer's disease (AD) pathology. Insomnia is a risk factor for AD, but the mechanism explaining this association remains unknown. Here, inflammation is proposed as a potential intermediate that could exacerbate the association between insomnia and AD pathology. Inflammation has already been linked to both insomnia and the progression of AD. In fact, insomnia is associated with increased inflammation, and enhanced inflammation has been associated to AD development. However, very few studies have examined inflammation as a potential process modifying the relationship between insomnia and AD pathology. It is noteworthy that this project does not directly measure the development of AD itself, but rather the development of the disease, which can appear up to decades before the first clinical signs. This highly preventive approach aims to identify risk factors before symptoms arise, allowing for earlier intervention. Therefore, this project is innovating in its attempt to determine whether inflammation, as measured by YKL-40, acts as a detrimental biological process with insomnia, promoting the development of AD. Understanding the role of insomnia and inflammation could provide a better insight into the disease progression and neuronal death involved in AD. This would offer us better resources, through information on sleep/inflammation, to detect the development of AD at earlier stages while also targeting insomnia and inflammation for preventive treatments, thereby reducing the prevalence of AD by addressing these adjustable factors.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530248
Name
Daoudi Rayan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluation of YKL-40 as a moderator variable between insomnia and the concentration of p-Tau217
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Blood; Elisa; Inflammation; Insomnia; P-Tau217; Simoa Hd-X; Ykl-40
Abstract
YKL-40 is a molecule whose blood concentration varies according to the severity of inflammation. We will attempt to assess whether inflammation, measured by blood levels of YKL-40, moderates the association between insomnia and Alzheimer's disease (AD) pathology. Insomnia is a risk factor for AD, but the mechanism explaining this association remains unknown. Here, inflammation is proposed as a potential intermediate that could exacerbate the association between insomnia and AD pathology. Inflammation has already been linked to both insomnia and the progression of AD. In fact, insomnia is associated with increased inflammation, and enhanced inflammation has been associated to AD development. However, very few studies have examined inflammation as a potential process modifying the relationship between insomnia and AD pathology. It is noteworthy that this project does not directly measure the development of AD itself, but rather the development of the disease, which can appear up to decades before the first clinical signs. This highly preventive approach aims to identify risk factors before symptoms arise, allowing for earlier intervention. Therefore, this project is innovating in its attempt to determine whether inflammation, as measured by YKL-40, acts as a detrimental biological process with insomnia, promoting the development of AD. Understanding the role of insomnia and inflammation could provide a better insight into the disease progression and neuronal death involved in AD. This would offer us better resources, through information on sleep/inflammation, to detect the development of AD at earlier stages while also targeting insomnia and inflammation for preventive treatments, thereby reducing the prevalence of AD by addressing these adjustable factors.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Daoudi, Rayan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~